Episode 102
On this week’s Biotech Hangout, hosts Chris Garabedian, Josh Schimmer, Brad Loncar, Eric Schmidt and Tim Opler kick off the episode with a spotlight on women’s health, which was sparked by Bayer’s Phase 3 data readouts for menopause symptoms. The group also cover Incyte’s $2B share repurchase which leads into a discussion on stock buybacks and the ‘broken’ R&D model. The group also recaps ASGCT 2024 and new gene editing technologies. In deals of the week, the hosts discuss deals and financings from the week, including Takeda and AC Immune’s $100M license agreement, Uniquity Bio’s $300M launch and J&J;s $850M purchase of Proteologix. In other data news, hosts discuss Merck’s TIGIT/PD-1 Phase 2 safety concerns, Ionis/Biogen discontinue ALS treatment, COVID-19 data from Shionogi and AstraZeneca, and a look at obesity ‘limited data’ versus Vertex’s data transparency. Other topics include Bolt Therapeutics discontinuing its oncology asset, Dynavax denied expanded use by FDA, Recursion’s stock surges with fastest supercomputer claim, and short selling and meme stocks in biotech. *This episode aired on May 17, 2024.
Available Results
Generated results are saved to the knowledge database for reuse and search.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.